Idiopathic Pulmonary Fibrosis Treatment | Ofev

About the Disease

Idiopathic Pulmonary Fibrosis (IPF) is a terminal disease in which lung tissue becomes thick and stiff or scarred over time, resulting in the inability to move oxygen to the brain and other parts of the body. Common symptoms include shortness of breath, a dry hacking cough, fatigue, unexplained weight loss, and muscle and joint aches. The condition is 'idiopathic' because the cause is unknown. Respiratory failure is the most common cause of death, which typically occurs within 3-5 years of diagnosis.

About our Patient Care

Our dedicated Care Team will work with the physician's office and insurance on a patient's behalf so that our patients have more time to focus on their treatment and quality of life. We are here to listen, provide

counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

As part of treatment, we provide:

Dedicated Care Team

We provide prescribers and patients with a dedicated care team for each of our disease state programs. This includes a primary pharmacy contact, clinical education, side-effects management, scheduled refill calls, and a direct phone, fax and email address.

In-Home Patient- and Family-Centric Care

We administer a nationwide nursing network, allowing patients to pursue in-home treatment or receive training on self-administrated drugs. Our nurses are ideally positioned to establish a partnership with patients and their families in order to provide clinical education and coaching that strengthen the patient's capacity to achieve therapy goals.

Shipping and Coordination of Care

We provide free overnight delivery of medications and necessary medical supplies and manage the coordination of care between prescribers, sites of care, nurses and patients to ensure dispenses and drug delivery align with the date and location of service.

Financial Assistance

We successfully identify and assist enrolling patients into any and all manufacturer co-pay and foundation support programs in order to minimize a potential financial burden to patients given the high-cost of specialty medications.